All Industries

Top Genomics Companies

103 Genomics companies, sorted by total funding raised.

Caris Life SciencesIPO

Provides comprehensive molecular profiling and AI-driven precision oncology services for physicia...

Irving, United States1001–5000Diagnostics, Genomics
Growth Equity·$1.5B·Apr 2025
Alnylam PharmaceuticalsIPO

Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...

Cambridge, United States1001–5000Biotech, Genomics
Corporate Round·$1.0B·Apr 2020
Pacific Biosciences

Long-read DNA sequencing company providing advanced systems for complete and accurate genome, tra...

Menlo Park, United States501–1000Biotech, Genomics
Convertible·$900.0M·Feb 2021
Tessera Therapeutics

Develops Gene Writing technology and non-viral delivery to create in vivo genetic medicines for m...

Somerville, United States201–500Biotech, Genomics
Corporate Round·$730.0M·Dec 2025
Mirador Therapeutics

Clinical-stage precision medicine company developing targeted therapies for immune-mediated infla...

San Diego, United States11–50Biotech, Drug Discovery
Series B·$650.0M·Oct 2025
Element Biosciences

Life science company democratizing access to advanced DNA sequencing tools with high-quality, aff...

San Diego, United States201–500Biotech, Genomics
Series D·$648.3M·Jul 2024
Ultima Genomics

Novel DNA sequencing architecture to scale the ultra low cost whole genome

Fremont, United States201–500Artificial Intelligence, Healthcare
Series A·$600.0M·May 2022
DNAnexus

Provides a cloud-based precision-health platform to manage, analyze, and collaborate on multi-omi...

Mountain View, United States201–500Data & Analytics, Developer Tools
Series G Plus·$572.0M·Mar 2022
Synthego

Provides CRISPR reagents, engineered nucleases, and GMP manufacturing to researchers and therapeu...

Redwood City, United States51–200Biotech, Genomics
Series E·$570.0M·Feb 2022
Helix

Population genomics and viral surveillance company enabling health systems and public health orga...

San Mateo, United States201–500Biotech, Diagnostics
Series C·$435.0M·Jun 2021
Verve TherapeuticsAcquired

Develops one-time in vivo gene-editing medicines to prevent and treat atherosclerotic cardiovascu...

Boston, United States201–500Biotech, Drug Discovery
Series C·$428.5M·Oct 2024
BillionToOneIPO

The genetic testing platform detecting and measuring disease.

Menlo Park, United States201–500Diagnostics, Genomics
Venture Unknown·$406.0M·Mar 2026
nChroma Bio

Genetic medicines company developing targeted in vivo delivery and engineered epigenetic silencer...

Boston, United States51–200Biotech, Genomics
Corporate Round·$335.0M·Dec 2024
Ohalo Genetics

Gene editing for plant breeding to create new crop varieties.

South San Francisco, United States51–200AgriTech, Gene Editing
Series C·$317.3M·Feb 2025
NateraIPO

Natera provides DNA testing across multiple clinical areas including women’s health and oncology.

San Carlos, United States5001–10000Diagnostics, Genomics
Series E·$310.1M·Jul 2019
Neuron23

Clinical-stage biotech developing precision medicines for genetically defined Parkinson’s disease...

South San Francisco, United States11–50Biotech, Drug Discovery
Series D·$310.0M·Jun 2025
GRAILIPO

Biotechnology company developing multi-cancer early detection blood tests using high-intensity ge...

Menlo Park, United States1001–5000Biotech, Genomics
Series D·$300.0M·May 2020
LifeMine Therapeutics

Clinical-stage biopharma mining fungal genomes to discover genetically-encoded small molecules fo...

Cambridge, United States51–200Biotech, Drug Discovery
Venture Unknown·$300.0M·Jan 2025
Sophia GeneticsIPO

AI-driven platform that analyzes genomic, radiomic, and multimodal healthcare data for hospitals,...

Lausanne, Switzerland201–500Artificial Intelligence, Data & Analytics
Series F·$245.8M·Oct 2020
Personal Genome DiagnosticsAcquired

Innovative genomic technologies to solve fundamental challenges in oncology

Baltimore, United States51–200Biotech, Cancer Diagnostics
Series C·$244.2M·Feb 2021
Ray Therapeutics

Developing novel optogenetic gene therapies for patients with blinding diseases.

Berkeley, United States11–50Biotech, Genomics
Series B·$241.0M·Apr 2026
Scipher Medicine

Precision immunology company using AI and clinico-genomic data to match autoimmune patients with ...

Boston, United States51–200Artificial Intelligence, Drug Discovery
Series D·$197.8M·Jul 2024
SpliceBio

SpliceBio is a biotechnology company exploiting Protein Splicing to develop next generation gene ...

Barcelona, Spain11–50biotech, gene therapy
Series B·$192.0M·Jun 2025
AviadoBio

AviadoBio is a biotechnology company developing transformative gene therapies for neurodegenerati...

London, United Kingdom51–200Biotech, Genomics
Series B·$168.5M·Apr 2025
Editas MedicineIPO

Clinical-stage biotechnology company developing CRISPR-based genomic medicines for people with se...

Cambridge, United States201–500Biotech, Genomics
Series B·$163.0M·Aug 2015